Proponents of cannabis use in a medical context have often suggested that it is a superior substitute of opioid for chronic pain management. Cannabis owes its analgesic properties to components called cannabinoids, with the two most prominent being cannabidiol (CBD) and tetrahydrocannabinol (THC). Both compounds have similar potential for treating chronic pain, however, while THC is addictive, CBD is not and therefore is of special clinical interest.
These compounds exert biological effects by binding and activating cannabinoid receptors in our bodies.
Two main subtypes of these receptors are type 1 (CB1), which are primarily located in the brain and type 2 (CB2), which are primarily located in the immune system. Therefore, several studies have suggested that cannabis can reduce both neuropathic pain, which is caused by damage or diseases affecting the somatosensory nervous system, by acting on CB1 and inflammatory pain, which is the hypersensitivity to pain caused by inflammation, by acting on CB2. However, the results of some of these studies lack statistical significance and findings from different studies are sometimes inconsistent. In addition, there also exists significant evidence of adverse side effects associated with cannabinoids treatment. For the above reasons, additional clinical research needs to be conducted before definite conclusions on the pain-relieving properties and medical application of cannabis can be reached.
As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products. At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market.
At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2025 All rights reserved. Patents pending. EO Care, Inc.
